Research programme: antibody therapeutics - Y-Biologics

Drug Profile

Research programme: antibody therapeutics - Y-Biologics

Alternative Names: AR 001; AR 003; YBL 001; YBL 002; YBL 003; YBL 004; YBL 005; YBL 006; YBL 007

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Y-Biologics
  • Developer Ahn-Gook Pharmaceutical; Y-Biologics
  • Class Antibodies; Biobetters; Drug conjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Autoimmune disorders; Multiple sclerosis

Most Recent Events

  • 10 Mar 2017 Research programme: antibody therapeutics - Y-Biologics is available for licensing as of 10 Mar 2017. http://ybiologics.com/eng/technology/pipeline.asp
  • 09 Mar 2017 Early research in Autoimmune disorders in South Korea (Parenteral) before March 2017
  • 09 Mar 2017 Early research in Multiple sclerosis in South Korea (Parenteral) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top